Melodiol Global Health (CHIA:ME1) - Stock Price, News & Analysis

ME1 Stock Overview

Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific.

About the company

ME1 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Does not have a meaningful market cap (A$1M)

Negative shareholders equity

Earnings have declined by 17.7% per year over past 5 years

Shareholders have been substantially diluted in the past year

+ 1 more risk

Melodiol Global Health Limited Competitors

Wellfully

ASX:WFL

AU$1.5m

Invex Therapeutics

ASX:IXC

AU$6.1m

Firebrick Pharma

ASX:FRE

AU$11.5m

Cann Global

ASX:CGB

AU$5.4m

Price History & Performance

Summary of all time highs, changes and price drops for Melodiol Global Health
Historical stock prices
Current Share Price	AU$0.001
52 Week High	AU$0.90
52 Week Low	AU$0.001
Beta	2.5
11 Month Change	0%
3 Month Change	-60.00%
1 Year Change	n/a
33 Year Change	-100.00%
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	ME1	AU Pharmaceuticals	AU Market
7D	0%	-6.3%	-0.7%
1Y	n/a	82.1%	17.1%

Return vs Industry: Insufficient data to determine how ME1 performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ME1 performed against the Australian Market.

Price Volatility

Is ME1's price volatile compared to industry and market?
ME1 volatility
ME1 Average Weekly Movement	66.0%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: ME1's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: ME1's weekly volatility has increased from 49% to 66% over the past year.

About the Company

Founded	Employees	CEO	Website
2015	n/a	Will Lay	melodiolglobalhealth.com

Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023.

Melodiol Global Health Limited Fundamentals Summary

How do Melodiol Global Health's earnings and revenue compare to its market cap?
ME1 fundamental statistics
Market cap	AU$1.13m
Earnings (TTM)	-AU$35.52m
Revenue (TTM)	AU$18.92m

0.1x

P/S Ratio

0.0x

P/E Ratio

Is ME1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ME1 income statement (TTM)
Revenue	AU$18.92m
Cost of Revenue	AU$18.10m
Gross Profit	AU$817.00k
Other Expenses	AU$36.34m
Earnings	-AU$35.52m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.032
Gross Margin	4.32%
Net Profit Margin	-187.73%
Debt/Equity Ratio	-232.0%

How did ME1 perform over the long term?

See historical performance and comparison

ME1 Stock Overview

Rewards

Risk Analysis

Melodiol Global Health Limited Competitors

ASX:WFL

AU$1.5m

ASX:IXC

AU$6.1m

ASX:FRE

AU$11.5m

ASX:CGB

AU$5.4m

Price History & Performance

Recent News & Updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Less than half of directors are independent

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.24

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

Shareholder Returns

Price Volatility

About the Company

Melodiol Global Health Limited Fundamentals Summary

0.1x

0.0x

Earnings & Revenue